Macrophage migration inhibitory factor expression in cervical cancer
Mathias Krockenberger1, Jörg B Engel, Julia Kolb
1Department of Obstetrics and Gynecology, University of Wuerzburg, Würzburg, Germany.
Journal of Cancer Research and Clinical Oncology
|November 17, 2009
Summary
Macrophage migration inhibitory factor (MIF) is overexpressed in cervical cancer, indicating its critical role in disease development. This finding suggests MIF as a potential therapeutic target for uterine cervical cancer.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Macrophage migration inhibitory factor (MIF) is a cytokine implicated in tumor progression and immune evasion in ovarian cancer.
- Uterine cervical cancer pathogenesis and immune escape mechanisms are significant areas of research.
Purpose of the Study:
- To investigate the role and expression of macrophage migration inhibitory factor (MIF) in uterine cervical cancer.
- To determine if MIF is overexpressed in cervical cancer tissues and cell lines.
Main Methods:
- Immunohistochemical analysis of MIF expression in 80 surgical biopsies of uterine cervical tissue (dysplasias, in situ, and invasive carcinomas).
- Western blotting, ELISA, and RT-PCR to analyze MIF protein and mRNA expression in SiHa and CaSki cervical cancer cell lines and their supernatants.
Main Results:
- MIF protein is significantly overexpressed in invasive cervical cancer compared to cervical dysplasias.
- MIF overexpression was confirmed at the mRNA level in invasive cervical cancer biopsies.
- Cervical cancer cell lines (SiHa, CaSki) exhibit MIF protein overexpression and secrete MIF.
Conclusions:
- Overexpression of MIF at both protein and mRNA levels, along with its secretion, highlights its critical role in uterine cervical cancer pathogenesis.
- MIF's known role in promoting tumor immune escape suggests it is a promising therapeutic target for cervical cancer.
